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Activated
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Leanne M. Johnson-Huang2, Mark J. Bluth1, James G. Krueger2, Michelle A. Lowes2 and John A. Carucci5
Tumor-associated macrophages (TAMs) may have an important role in tumor immunity. We studied the
activation state of TAMs in cutaneous SCC, the second most common human cancer. CD163 was identified as a
more abundant, sensitive, and accurate marker of TAMs when compared with CD68. CD163þ TAMs produced
protumoral factors, matrix metalloproteinases 9 and 11 (MMP9 and MMP11), at the gene and protein levels.
Gene set enrichment analysis (GSEA) was used to evaluate M1 and M2 macrophage gene sets in the SCC genes
and to identify candidate genes in order to phenotypically characterize TAMs. There was coexpression of CD163
and alternatively activated ‘‘M2’’ markers, CD209 and CCL18 (chemokine (C-C motif) ligand 18). There was
enrichment for classically activated ‘‘M1’’ genes in SCC, which was confirmed in situ by colocalization of CD163
and phosphorylated STAT1 (signal transducer and activator of transcription 1), IL-23p19, IL-12/IL-23p40, and
CD127. Also, a subset of TAMs in SCC was bi-activated as CD163þ cells expressed markers for both M1 and M2,
shown by triple-label immunofluorescence. These data support heterogeneous activation states of TAMs in
SCC, and suggest that a dynamic model of macrophage activation would be more useful to characterize TAMs.
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INTRODUCTION
Cutaneous squamous cell carcinoma (SCC) is the second
most common human cancer, affecting 4300,000 indivi-
duals in the United States annually (Weinberg et al., 2007;
Brantsch et al., 2008). Although most cases can be treated
successfully by surgical removal, certain aggressive cases can
cause extensive tissue destruction and metastasize to local
lymph nodes and distant organs. These aggressive cases are
responsible for B10,000 non-melanoma skin cancer deaths
in the United States each year. Aggressive behavior by SCC is
observed in solid organ-transplant recipients (Carucci, 2004).
Based on the potential for the host immunity to regulate
tumor behavior in SCC, it is important to characterize the
tumor-associated immune microenvironment.
Macrophages are one of the major populations of tumor-
infiltrating leukocytes associated with solid tumors (Gordon
and Taylor, 2005). Macrophages that infiltrate and surround
tumor nodules are defined as tumor-associated macrophages
(TAMs) (Wang et al., 2010), and different studies have shown
that macrophages may either inhibit or stimulate tumor
growth. Initially, TAMs were shown to participate in the early
eradication of tumor cells in vitro (Romieu-Mourez et al.,
2006). However, other studies have suggested that TAMs may
contribute to carcinogenesis, as there is a positive correlation
between increased numbers of TAMs and poor prognosis in
some human cancers (Leek et al., 1996; Bingle et al., 2002;
Sica et al., 2006; Lin and Pollard, 2007; Shabo et al., 2008;
El-Rouby, 2010; Nonomura et al., 2010; Steidl et al., 2010).
TAMs can fail to recognize tumor antigens (Fadok et al.,
1998) and may release factors that directly stimulate tumor
growth and angiogenesis (Lin et al., 2006; Lin and Pollard,
2007). Furthermore, the tumor itself can create a dynamic
microenvironment that can transform TAMs (Gocheva et al.,
2010). Thus, TAMs in the SCC microenvironment may be
associated with tumor growth.
Currently, the general classification of macrophage
activation parallels the Th1/Th2 paradigm, defining
classically activated (M1) and alternatively activated (M2)
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cells (Mantovani et al., 2004; Mosser and Edwards, 2008).
Classically activated macrophages are induced by IFN-g and
have a high capacity to present antigen. Alternatively
activated macrophages are induced by the cytokine IL-4,
which promotes type 2 responses. As SCCs usually progress,
in association with a Th2 microenvironment and low levels of
IFN-g, it is thought that the net immune response is ineffective
at suppressing tumor growth. Hence, TAMs have commonly
been considered alternatively activated or strongly skewed
to the M2 phenotype (Biswas et al., 2006; Martinez et al.,
2009; Siveen and Kuttan, 2009; Gordon and Martinez,
2010). However, there has been renewed debate over the
phenotypic activation of TAMs as the physiology of these
macrophages has been shown to change over time and to
demonstrate remarkable plasticity (Mosser and Edwards,
2008).
Given the importance of TAMs contributing to tumor
growth, and the current conflicting state of the understanding
of TAM activation, we set out to phenotypically characterize
macrophages in SCC. Initially, we used a nonbiased genomic
approach to guide our choice of markers to further evaluate
TAMs. ‘‘M1’’ and ‘‘M2’’ activated macrophage gene sets
(Fuentes-Duculan et al., 2010) were analyzed in our SCC
genomic phenotype (Haider et al., 2006) using gene set
enrichment analysis (GSEA) (Subramanian et al., 2005;
Bluth et al., 2009). We then identified candidate genes that
were expressed in the macrophage and SCC gene sets and
performed immunofluorescence on SCCs versus CD163, as
our constitutive macrophage marker.
Previously, we have shown that in normal skin and
psoriasis, CD163 is the most useful marker of dermal
macrophages (Zaba et al., 2007). We expanded on that
work to characterize TAMs in human SCC. We found the
following: (1) compared with CD68, CD163 was a more
abundant, sensitive, and accurate marker of TAMs; (2) there
was an increase in the protumoral factors matrix metallopro-
teinases 9 and 11 (MMP9 and MMP11) in SCC, and CD163þ
TAMs produced MMP9 and MMP11; (3) there was coexpres-
sion of CD163 and alternatively activated ‘‘M2’’ markers,
CD209 and CCL18 (chemokine (C-C motif) ligand 18);
(4) there was enrichment for classically activated ‘‘M1’’
genes in SCC, which was confirmed in situ by colocalization
of CD163 and phosphorylated STAT1 (STAT1p), IL-23p19,
IL-12/IL-23p40, and CD127; and (5) a subset of TAMs in SCC
was bi-activated as CD163þ cells expressed markers for both
M1 and M2, shown by triple-label immunofluorescence.
These data support heterogeneous activation states of TAMs
in SCC, and suggest that a dynamic model of macrophage
activation would be more useful to characterize TAMs.
Furthermore, driving TAM activation toward a more domi-
nant anticancer phenotype might be a potential therapeutic
strategy.
RESULTS
Macrophages were more abundant in SCC compared
with normal skin
Macrophages were quantified in SCC and normal skin
(n¼8–18) using CD163, which we consider a reliable marker
of macrophages in normal skin and psoriasis, and CD68, the
widely accepted macrophage marker (Zaba et al., 2007;
Bluth et al., 2009; Fuentes-Duculan et al., 2010). Represen-
tative immunohistochemistry is shown for CD163 and CD68,
and cell counts of the cases are presented (Figure 1a and b).
The vast majority of CD163þ and CD68þ macrophages
were surrounding, rather than infiltrating, the SCC tumor
nests, and both CD163þ and CD68þ macrophages were
significantly increased, B2-fold, in SCC compared with
normal skin (Po0.001 for both). Additionally, using double-
label immunofluorescence, CD163 colocalized with CD68
but there were CD163þ cells that did not coexpress CD68,
suggesting that CD163 is a more robust and sensitive marker
of macrophages in the skin than CD68 (Figure 1c). We also
evaluated the coexpression of CD163 with the well-known
dendritic cell (DC) marker, CD11c (Bluth et al., 2009). As we
have previously shown in normal skin (Zaba et al., 2007),
CD163þ cells in SCC also did not colocalize with this DC
marker (Figure 1d), demonstrating that these are two distinct
leukocyte populations. In contrast, CD68þ cells close to SCC
tumor nests did show colocalization with CD11c (Figure 1e).
SCC TAMs expressed protumoral products in the tumor
microenvironment
TAMs may produce factors that encourage tumorigenesis. We
have shown that SCC TAMs produce the prolymphangiogenic
factor vascular endothelial growth factor-C, which favors
tumor growth and development (Moussai et al., 2011).
MMPs, the enzymes that may contribute to tumor invasion
by degrading the matrix surrounding tumor nodules, may also
be produced by TAMs in SCC. MMP1, MMP10, and MMP13
genes have been shown to be upregulated in SCC (Haider
et al., 2006). MMP9 (gelatinase B) and MMP11 (stromelysin-3)
proteins correlate with increased tumor aggressiveness (Pinto
et al., 2003; Buergy et al., 2009; Shah et al., 2010; Steidl
et al., 2010; Zhao et al., 2010). Neither MMP9 nor MMP11
have been classified as products representative of either state
of macrophage activation. We showed that there was
increased gene expression by reverse transcriptase-PCR (RT-
PCR) of MMP9 in SCC compared with adjacent nontumoral
skin and normal skin (P¼ 0.07 and 0.008, respectively,
Figure 2a). Similarly, MMP11 was also increased in SCC
compared with adjacent nontumoral skin and normal skin
(P¼0.003 and 0.025, respectively, Figure 2b). We then asked
whether TAMs could be a possible source of the increased
MMP9 and MMP11. There was abundant colocalization of
MMP9 and MMP11 with CD163þ macrophages in SCCs
compared with normal skin (Figure 2c and d). These findings
suggest that TAMs secrete protumoral products in the SCC
microenvironment.
SCC TAMs expressed products of alternatively activated
macrophages
We evaluated expression of STAT6p based on the association
of Th2 cells and the tumor microenvironment (Todaro et al.,
2008; de Oliveira et al., 2009). STAT6 has an important
role in signaling pathways that lead to the differentiation
of Th2 cells, and STAT6p translocates to the nucleus in
www.jidonline.org 1323
JS Pettersen et al.
TAMs in SCC
IL-4-activated cells (Takeda et al., 1996; Forbes et al., 2010).
STAT6p colocalization with CD163 was abundant in the
inflammatory infiltrate associated with SCC compared with
normal skin (Figure 3a), suggesting the presence of IL-4
activation in TAMs.
To further evaluate the tumor microenvironment, we used
M1 and M2 gene sets to correlate with the SCC genomic
phenotype using GSEA (Subramanian et al., 2005; Lamb
et al., 2006; Bluth et al., 2009). We have used this approach
previously (Bluth et al., 2009), and have described it
thoroughly in a previous publication (Suarez-Farinas et al.,
2010). Fuentes-Duculan et al. (2010) recently published these
sets of genes defining ‘‘M1’’ macrophages, induced with
IFN-g, and ‘‘M2’’ macrophages, induced with IL-4, compared
with control. We hypothesized that there should be greater
expression of M2 macrophage genes in the SCC genomic
phenotype (Martinez et al., 2009; Siveen and Kuttan, 2009),
defined by the SCC versus normal skin genes (Subramanian
et al., 2007). However, the M2 gene set was not significantly
enriched in SCC genomic phenotype, which may reflect that
the M2 gene set is similarly expressed in both SCC and
normal skin.
Despite the lack of enrichment of M2 genes in the SCC
transcriptome, some published M2 genes (Martinez et al.,
2006) were upregulated in our M2 gene set (Table 1),
including CD209 (DC-SIGN) (Soilleux et al., 2002; Puig-
Kroger et al., 2004), CCL17 (Bonecchi et al., 1998; Katakura
et al., 2004), and CCL18 (Kodelja et al., 1998; Mantovani
et al., 2004; Martinez et al., 2006; Gustafsson et al., 2008;
Kwan et al., 2008). By double-label immunofluorescence,
CD163þ cells colocalized with CD209 and CCL18 in SCC
and to a lesser extent in normal skin (Figure 3b and c). In the
SCC microenvironment, we have thus shown that TAMs
expressed some surface markers (CD209) and chemokines
(CCL18) of M2-type macrophages. In addition and consistent
with previous findings (Schutyser et al., 2005), we showed













































Figure 1. Macrophages were more abundant in squamous cell carcinoma (SCC) compared with normal skin. Representative immunohistochemistry ( 10)
and cell counts of the macrophage markers (a) CD163 (with an inset of CD163þ cells at  20) and (b) CD68, showing a significantly increased number of
macrophages surrounding SCC tumor nests compared with normal skin. Each dot represents one patient. ***Po0.001. (c) CD163 (green) colocalized with
CD68 (red) shown as yellow, but there were CD163þ cells that did not coexpress CD68. (d) CD163 (green) did not coexpress CD11c (red), whereas
(e) some CD68þ cells (green) did coexpress CD11c (red) shown as yellow. Bar¼ 100mm.
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SCC TAMs expressed characteristics of classically activated
macrophages in a microenvironment with type 1 activation
Although there was not any significant enrichment of M2
macrophage genes in the SCC genomic phenotype, the GSEA
results did indicate that M1 macrophage gene sets were
significantly enriched in the SCC genomic phenotype
(Supplementary Table S1 online). Table 1 lists selected genes
that were upregulated in both the M1 gene sets and the SCC
versus normal skin transcriptome, indicating an M1-type
macrophage activation pattern in the SCC microenvironment.
It was perhaps surprising that there was such a marked M1
genomic signature in SCC. However, several recent studies
have shown that IFN-g-producing T cells can be found in
SCCs and other tumors (Li-Weber and Krammer, 2003;
Huang et al., 2009; Kryczek et al., 2009; Koller et al., 2010).
To confirm that macrophages in the SCC tumor micro-
environment could be responsive to IFN-g, we performed
double-label immunofluorescence with CD163 and the two
requisite chains of the IFN-g receptor. The IFN-g receptor 1
subunit (IFNgR1) that is internalized upon binding with
IFN-g (Schroder et al., 2004) was present in the majority of
macrophages in SCC compared with macrophages in normal
skin, which did not express this receptor (Supplementary
Figure S1a online). There is a second chain of IFNg receptor,
IFNgR2, that showed a similar pattern of colocalization
with CD163þ cells in SCC compared with normal skin
(Supplementary Figure S1b online). CD68þ macrophages in
SCC also strongly expressed IFNgR1 and IFNgR2 compared
with normal skin (Supplementary Figure S1c and d online).
These data indicate that SCC TAMs are capable of responding
to IFN-g. STAT1 and myxovirus resistance 1, the well-
recognized IFN-g-induced genes (Landolfo et al., 1995; Saha
et al., 2010), were upregulated in the M1 gene set and SCC
transcriptome (Table 1). STAT1p, the form of STAT1 that
translocates to the nucleus in IFN-g-activated cells, showed
minimal expression in normal skin, but colocalized with
CD163 in the juxtatumoral dermis of SCC (Figure 4a),
indicating that CD163þ macrophages in SCC were indeed
responding to IFN-g.
To further classify these SCC TAMs, the expression of
markers and cytokines on TAMs considered to be represen-
tative of classical/M1 macrophage activation were evaluated
(Table 1) (Martinez et al., 2006). There was increased gene
expression of the marker CD127 (IL-7 receptor) and the
cytokine subunits, IL-23p19 and IL-12/23p40, in the M1
macrophage gene set and increased gene expression of
IL-23p19 in the SCC transcriptome (Table 1). The expression
of CD127 has been shown to be strongly downregulated by
IL-4 (Crawley et al., 2010), which supports its role as an M1
marker. We confirmed these findings at the protein level by
double-label immunofluorescence. CD163þ TAMs abun-
dantly coexpressed CD127 and produced IL-23p19 and
IL-12/IL-23p40 compared with normal skin CD163þ macro-
phages (Figure 4b–d). Thus, in the SCC microenvironment,
TAMs express surface markers (CD127) and cytokines (IL-23
subunits) of M1-type activated macrophages.
A subset of SCC TAMs simultaneously expressed markers of
both classical and alternative activation
We have shown that TAMs in the SCC environment exhibit
characteristics of both classical and alternative activation.
However, it was not clear if there were two separate
populations of macrophages driven by each cytokine, or
if one subset of macrophages was responding to both
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Figure 2. Squamous cell carcinoma (SCC) tumor-associated macrophages (TAMs) expressed protumoral products in the tumor microenvironment. Mean
mRNA expression of (a) matrix metalloproteinase 9 (MMP9) and (b) MMP11 relative to Human Acidic Ribosomal Protein (HARP) after adjustment for batch
effect in normal skin (white bars), nontumoral skin (NT, gray bars), and SCC (black bars) with SEM. *Po0.05, **Po0.01. CD163þ cells (green) demonstrated
abundant colocalization with (c) MMP9 (red) and (d) MMP11 (red) in SCC compared with normal skin. Double-positive cells appear yellow. Bar¼ 100mm.
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cytokines simultaneously. Using triple-label immunofluores-
cence and confocal imaging, some CD163þ cells were
identified that colocalized with both STAT1p and STAT6p
(shown by white arrows, Figure 5a), indicating that some
SCC TAMs respond to both Th1 and Th2 signals and that
there is a complex SCC tumor microenvironment of mixed
Th1 and Th2 activation.
To further evaluate the TAM phenotype in this setting, we
also identified a subpopulation of CD163þ macrophages that
coexpressed both CD127 (upregulated in M1 macrophages)
and CD209 (upregulated in M2 macrophages) (shown by
white arrows, Figure 5b). There were also CD163þ cells that
colocalized with CD127 only (yellow cells) and CD163þ
cells that colocalized with CD209 (dark teal cells). This
suggests that macrophage activation in SCC is heterogeneous,
as we found several types of TAMs: M1 macrophages
responding to Th1 signals, M2 macrophages responding
to Th2 signals, and bi-activated macrophages responding to
both Th1 and Th2 cytokines simultaneously.
DISCUSSION
Our studies suggest that CD163 should be considered the
superior marker to identify TAMs in SCC. First, CD163þ
TAMs were prominent and more abundant in the cutaneous
SCC tumor microenvironment and significantly increased
compared with macrophages in normal skin. Second, CD163
is the most sensitive marker for TAMs in SCC, as it identifies
more dermal macrophages surrounding the tumor nodules
than CD68. Third, CD163 is a more accurate marker of
TAMs, because it did not colocalize with CD11cþ DCs in
SCC, compared with CD68, which showed some overlap.
This is similar in psoriasis, where CD163 had the least
overlap with CD11c (Fuentes-Duculan et al., 2010).














Figure 3. Squamous cell carcinoma (SCC) tumor-associated macrophages
(TAMs) expressed products of alternatively activated macrophages. Many
CD163þ cells (green) coexpressed (a) phosphorylated signal transducer and
activator of transcription 6 (STAT6p; red), (b) CD209/DC-SIGN (red), and (c)
chemokine (C-C motif) ligand 18 (CCL18; red) compared with normal skin.
Double-positive cells appear yellow. Bar¼ 100 mm.
Table 1. Representative upregulated genes in the M1











STAT1 8.51 5 2.47
Mx-1 19.03 5 2.89
IL-23p19 3.10 5 2.34
IL-12/IL-23p40 3.36 5 1.11
CD127 4.44 5 7
M2
CD209 4 9.25 7
CCL18 4 3.43 3.558
CCL17 4 2.58 1.43
Abbreviations: CCL18, chemokine (C-C motif) ligand 18; Mx-1, myxovirus
resistance 1; SCC, squamous cell carcinoma; STAT1, signal transducer
and activator of transcription 1.
1Fuentes-Duculan et al., 2010.
2Haider et al., 2006.
3Genes representative of M1 and M2 macrophages were selected and
their fold change in the M1 and M2 gene sets and the SCC transcriptome
are listed.
4Genes not differentially expressed in the M1 gene set compared
with control.
5Genes not differentially expressed in the M2 gene set compared with
control.
6SCC versus normal skin transcriptome, fold change and false discovery
rate (FDR) o0.05.
7HU95 chip did not include this probe.
8FDR 40.05.
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macrophage marker solely for alternative activation,
we have shown that CD163 not only identifies alternatively
activated macrophages, but also classically and bi-activated
macrophages in SCC. These findings suggest that future
studies could benefit from using CD163 as a pan-macrophage
marker in the skin.
To understand the cellular state of macrophage activation
in the cutaneous SCC microenvironment, we must consider
the setting in which these TAMs exist (Figure 5c). The
tumor microenvironment is defined as a mixture of tumor
and nontumor cells at the dynamic interface of neoplasia
(van Kempen et al., 2003). Previous studies have docu-
mented an influx of IFN-g-producing cells in the tumor


















Figure 4. SCC tumor-associated macrophages (TAMs) expressed
characteristics of classically activated macrophages in a microenvironment
with type 1 activation. Compared with normal skin, CD163þ cells
coexpressed (a) phosphorylated signal transducer and activator of
transcription 1 (STAT1p; red), (b) CD127/IL7R (red), (c) IL-23p19 (red),
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IL4-RIFN-γR
Figure 5. A subset of SCC tumor-associated macrophages (TAMs)
simultaneously expressed characteristics of both classical and alternative
activation. Triple-labeled confocal immunofluorescence revealed the
presence of (a) CD163þ cells (blue) that simultaneously coexpressed
phosphorylated signal transducer and activator of transcription 6
(STAT6p; green) and STAT1p (red) and (b) CD163þ cells (green) that
simultaneously coexpressed the markers CD127 (red) and CD209 (blue)
in SCC. Triple-positive cells (white) are indicated by arrows. Bar¼ 100mm.
(c) The proposed model of SCC macrophage polarization. Th1 and Th2 cells
produce cytokines, IFN-g and IL-4, respectively, and act on resident CD163þ
macrophages to polarize these cells in several directions. IFN-g stimulates
the M1 phenotype (CD127 and IL-23), and IL-4 stimulates toward the
M2 phenotype (CD209 and chemokine (C-C motif) ligand 18 (CCL18)).
There is also production of mediators that are not driven by known
polarizing cytokines, such as matrix metalloproteinase 9 (MMP9), MMP11,
and vascular endothelial growth factor-C (VEGF-C). The overall outcome
is a poly-activated TAM.
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IFN-g genomic signature in the SCC tumor microenvironment
coupled with evidence of upregulated IFN-g receptors and
abundant IFN-g activation of the infiltrating TAMs, indicating
a Th1-type immune environment. However, the tumor
microenvironment also has increased levels of Th2 cytokines
(IL-4 and IL-10) produced by both immune and tumor cells
(Lathers and Young, 2004; Pries and Wollenberg, 2006;
Todaro et al., 2008; Bluth et al., 2009). In our study, there
was Th2 activation shown by phosphorylated STAT6 and
CCL18 coexpression by CD163þ macrophages. Thus, these
data suggest that TAMs in SCC respond to a dynamic mix of
Th1 and Th2 signals.
These studies show that in normal skin at steady state,
there is a predominant Th2/M2 environment. In contrast, SCC
TAMs demonstrate features of both M1 and M2 activation.
Conventionally, strong Th1/M1 responses should prevent
tumor progression (Hung et al., 1998). Furthermore, in
imiquimod-treated SCC, increased levels of IFN-g in SCC
induced antitumor effects and inhibited tonic anti-inflamma-
tory signals of IL-10 (Huang et al., 2009). However, despite
the presence of a strong M1 signal, the natural history of
SCC is usually tumor progression, and hence this M1 signal
is not able to eradicate the tumor. The mechanism for the
ineffectiveness of Th1/M1 macrophages in eradicating the
tumor is not clear, but may be because of the imbalance of
Th1 and Th2 cytokines and their effects on TAMs.
Our study provides insight into the heterogeneous
phenotypes and functions of TAMs. The effect of M1 and
M2 TAMs may be to amplify immune responses to the tumor
by inducing chemotaxis and activation of infiltrating T cells.
The abundant influx of macrophages into the tumor micro-
environment can also help promote tumor growth by
stimulating angiogenesis and tissue remodeling. The protu-
moral role of TAMs in SCC is supported by the production of
prolymphangiogenic factors such as vascular endothelial
growth factor-C (Moussai et al., 2011). Our observation that
TAMs produce MMP9 and MMP11 also supports their
protumoral role, as MMPs facilitate direct tumor spread and
release of matrix-sequestered angiogenic factors that encou-
rage tumor growth (Egeblad and Werb, 2002). Also, it is
possible that tumors may produce factors that act on TAMs
in a paracrine fashion (Balkwill and Mantovani, 2001).
A positive correlation between increased numbers of macro-
phages and poor prognosis in various human cancers has
been demonstrated (Bingle et al., 2002; Sica et al., 2006; Lin
and Pollard, 2007; Shabo et al., 2008; El-Rouby, 2010;
Nonomura et al., 2010; Steidl et al., 2010). It is possible that
the weaker classical activation state favors production
of procarcinogenic growth factors by TAMs. Based on this,
the potential to induce a more dominant M1 activation state
in TAMs could be pursued as a promising target for
therapeutic interventions.
There has been much debate over the phenotypic
activation of TAMs as the physiology of macrophages has
been shown to demonstrate remarkable plasticity (Mosser
and Edwards, 2008; Siveen and Kuttan, 2009). Critics of the
current linear model of macrophage polarization argue that
the model does not allow for the plethora of possible
macrophage activation states and capabilities. Our evidence
suggests that the activation state of a macrophage cannot
be pigeonholed into one category, and that the linear model
of macrophage activation may not encompass all the
potential roles of the macrophage. Therefore, we favor the
dynamic color wheel model of macrophage activation
proposed by Mosser and Edwards (2008) as it accommodates
the chameleon-like properties of this cell (Stout and Suttles,
2004).
MATERIALS AND METHODS
Institutional review board approval (Weill Cornell Medical College)
and informed consent was obtained before enrolling patients in this
study, and the study adhered strictly to the Declaration of Helsinki
Principles.
Samples used in the study
For immunohistochemistry and immunofluorescence, cutaneous
nodular stage 1 SCC samples were obtained during Mohs micro-
graphic surgery (n¼ 3–18). Tumors were obtained from sun-exposed
regions, namely head, neck, and dorsal hands. All tumors were
o2 cm on examination and showed dermal invasion on light
microscopy. Ten normal specimens were obtained via punch
biopsies from non-sun-exposed areas of patients without skin cancer
and normal abdominoplasty tissue.
Immunohistochemistry and immunofluorescence
Standard procedures were used for immunohistochemistry as
described (Bluth et al., 2009). Normal skin and SCC (n¼ 8–18) were
stained with macrophage markers CD163 and CD68 (antibodies in
Supplementary Table S2 online) and a counterstain. Normal
papillary dermis, designated as the tissue extending from the
epidermal–dermal border to 100 mm deep to the epidermis, and
SCC ‘‘juxtatumoral dermis,’’ defined as the dermis 100 mm circum-
ferential to the tumor, were examined as previously described
(Kaporis et al., 2007). Positive cells were counted using NIH IMAGE
J software (Bethesda, MD), and cell counts per unit area
(mm2 100,000) were determined. Immunofluorescence stains were
carried out in a standard manner (Fuentes-Duculan et al., 2010)
(Supplementary Table S2 online). Images were acquired using either
Zeiss Axioplan 2 widefield fluorescence microscope (Thornwood,
NY) or upright confocal microscope. Dermal collagen fibers gave
green autofluorescence, and antibodies conjugated with fluoro-
chromes often gave background epidermal fluorescence. Single stain
controls and isotype controls were performed for the confocal
images (Supplementary Figure S2 online).
Gene array analysis
SCC microarray data have been previously published (Haider et al.,
2006). To estimate the fold change of SCC versus normal skin, a
moderated t-test available in limma package from R/Bioconductor
(Seattle, WA) was used, and genes were considered significant with a
fold change 42 and false discovery rate o0.05. GSEA was used to
evaluate the enrichment of the macrophage transcriptomes in the
SCC genomic phenotype (as defined by SCC vs. normal fold change
by microarray) as in a previous publication by our group (Suarez-
Farinas et al., 2010) using GSEA desktop application (Lamb et al.,
2006; Suarez-Farinas et al., 2010). The genomic transcriptomes of
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M1 and M2 macrophages derived from in vitro cytokine-stimulated
macrophages have been published (Fuentes-Duculan et al., 2010).
Macrophages were polarized by adding IFN-g, IL-4, tumor necrosis
factor-a, lipopolysaccharide, and lipopolysaccharide plus IFN-g, and
then compared with control macrophages. There were 585
upregulated and 334 downregulated probes in the M1 macrophages,
respectively, and 132 upregulated and 29 downregulated probes in
the M2 macrophages, respectively (Fuentes-Duculan et al., 2010).
RT-PCR
RNA was extracted from paired SCC and nontumoral skin samples
meeting the above inclusion criteria (n¼ 15) and normal skin from
healthy volunteers (n¼ 10), using the RNeasy Mini KIT (Qiagen,
Valencia, CA). RT-PCR was performed as previously described
(Chamian et al., 2005; Fuentes-Duculan et al., 2010). The PCR was
performed in two batches. The first group was 10 paired SCC and
nontumoral skin, and 2 normals, and the second group was 5 paired
SCC samples (described in Moussai et al., 2011) and 8 normal skin RNA.
The primers for MMP9 and MMP11 were from Applied Biosystems,
Foster City, CA (Hs00957562_m1 and Hs00171829_m1, respectively),
normalized to Human Acidic Ribosomal Protein housekeeping gene. As
samples were obtained at two different time points, the log2 data were
adjusted using a linear model to account for the batch effect.
Statistics
Cell counts were analyzed using Mann–Whitney U-test, and P-values
reported. Logarithmic RT-PCR data were analyzed using paired t-test
for SCC versus nontumoral skin and unpaired t-test to compare with
normal skin control.
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